High-resolution analysis of HLA class I alterations in colorectal cancer

Dierssen, Jan Willem F; Miranda, Noel F C C de; Mulder, Arend; Puijenbroek, Marjo van; Verduyn, W.; Claas, Frans H.J.; Velde, Cornelis J.H. van de; Fleuren, Gert Jan; Cornelisse, Cees J.; Corver, Willem E.; Morreau, Hans

doi:10.1186/1471-2407-6-233

Cited by 18 publications

(15 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The β2m gene mutations may be preferentially selected by T cell selective pressure. In this regard, the impairment of HLA class I antigen expression is a frequent even in MSI (+) colon carcinoma [140] and predominantly mediated by frameshift mutations of the β2m gene [137, 141, 142] likely reflecting immunoselective pressure. In view of these findings, the outgrowth of MSI (+) colon carcinoma cells that lack HLA class I as well as class II antigen expression is compatible with the selection of HLA class I and class II antigen-deficient tumor cells during MSI (+) colon carcinoma tumorigenesis.…”

Section: Role Of Immune Selective Pressure In the Hla Antigen And Nkcmentioning

confidence: 99%

HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition

Campoli

Ferrone

2011

Semin Immunopathol

View full text Add to dashboard Cite

Malignant transformation of cells is often associated with changes in classical and non-classical HLA class I antigen, HLA class II antigen as well as NK cell activating ligand (NKCAL) expression. These changes are believed to play a role in the clinical course of the disease since these molecules are critical to the interactions between tumor cells and components of both innate and adaptive immune system. For some time, it has been assumed that alterations in the expression profile of HLA antigens and NKCAL on malignant cells represented loss of classical HLA class I antigen and induction of HLA class II antigen, non-classical HLA class I antigen and/or NKCAL expression. In contrast to these assumptions, experimental evidence suggests that in some cases dysplastic and malignant cells can acquire classical HLA class I antigen expression and/or lose the ability to express HLA class II antigens. In light of the latter findings as well as of the revival of the cancer immune surveillance theory, a reevaluation of the interpretation of changes in HLA antigen and NKCAL expression in malignant lesions is warranted. In this article, we first briefly describe the conventional types of changes in HLA antigen and NKCAL expression that have been identified in malignant cells to date. Second, we discuss the evidence indicating that, in at least some cell types, classical HLA class I antigen expression can be acquired and/ or the ability to express HLA class II antigens is lost. Third, we review the available evidence for the role of immune selective pressure in the generation of malignant lesions with changes in HLA antigen expression. This information contributes to our understanding of the role of the immune system in the control of tumor development and to the optimization of the design of immunotherapeutic strategies for the treatment of cancer.

show abstract

Section: Role Of Immune Selective Pressure In the Hla Antigen And Nkcmentioning

confidence: 99%

HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition

Campoli

Ferrone

2011

Semin Immunopathol

View full text Add to dashboard Cite

show abstract

“…While the loss of MHC class I expression in human tumors is not definitive evidence of immunoediting, this widely observed defect remains some of the best to date. Loss of MHC class I in human tumors is frequently observed in several cancers including B cell lymphomas, colorectal, ovarian, breast, melanoma, lung and renal cancers [95][96][97][98][99][100][101][102][103][104][105][106][107][108][109][110][111][112][113]. Ongoing studies continue to define the molecular mechanisms of downregulation of MHC molecules.…”

Section: C122 Editing For Reduced Mhc and Antigen Expression And mentioning

confidence: 99%

Tumor immunoediting and immunosculpting pathways to cancer progression

Reiman

Kmieciak

Manjili

et al. 2007

Seminars in Cancer Biology

170

130

View full text Add to dashboard Cite

Recent studies have suggested that a natural function of the immune system is to respond and destroy aberrant, dysfunctional cells by a process called immunosurveillance. These studies also suggest that the tumors that arise despite immunosurveillance have been immunosculpted by the immune system. The purported abilities of tumors to induce immune tolerance and suppression, the increased pathogenic behavior of the tumor cells following exposure to immune effectors and the loss of immunogenicity (i.e. immunoediting) often observed in advanced stage tumors could be the result of immunosculpting. In some cases, these immunosculpting features may be permanent and irreversible. However, in other cases, reversible epigenetic mechanisms may underlie the immune resistant tumor phenotype. Regardless, these immune-induced alterations could contribute to cancer pathogenesis. Understanding the mechanisms by which tumors evade immunity will be important for disease prevention and therapeutics.

show abstract

“…Various studies have identified HLA alterations in colorectal cancer [19-21], including the prevalence of HLA class I alterations in MSI-H tumors [8,22]. However, the latter studies did not compare the frequency of alterations between hereditary and sporadic MSI-H tumors neither the mechanisms that led to HLA class I alterations in each subgroup.…”

Section: Introductionmentioning

confidence: 99%

HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression

et al. 2007

Self Cite

View full text Add to dashboard Cite

Background: Abnormalities in Human Leukocyte Antigen (HLA) class I expression are common in colorectal cancer. Since HLA expression is required to activate tumor antigen-specific cytotoxic Tlymphocytes (CTL), HLA class I abnormalities represent a mechanism by which tumors circumvent immune surveillance. Tumors with high microsatellite instability (MSI-H) are believed to face strong selective pressure to evade CTL activity since they produce large amounts of immunogenic peptides. Previous studies identified the prevalence of HLA class I alterations in MSI-H tumors. However, those reports did not compare the frequency of alterations between hereditary and sporadic MSI-H tumors neither the mechanisms that led to HLA class I alterations in each subgroup.

show abstract

High-resolution analysis of HLA class I alterations in colorectal cancer

Cited by 18 publications

References 40 publications

HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition

HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition

Tumor immunoediting and immunosculpting pathways to cancer progression

HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression

Contact Info

Product

Resources

About